Related Experiment Video
Updated: Jan 6, 2026
Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
Published on: January 3, 2020
Inhibitory effects of UM-C162 on Staphylococcus aureus alpha-toxin-induced toxicity
Jing Xuan Chong1, Cheng Hong Yap2, See Khai Lim3
1Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Abstract:
Staphylococcus aureus is a leading cause of nosocomial and community-acquired infections. The increasing prevalence of methicillin-resistant S. aureus and vancomycin-resistant S. aureus strains underscores the urgent need for novel anti-virulence agents. UM-C162, a recently identified small molecule, has been shown to suppress S. aureus biofilm formation and virulence in a Caenorhabditis elegans infection model. Transcriptomic and biochemical analyses revealed that UM-C162 disrupts the production of S. aureus haemolysins, proteases, and clumping factors. In this study, UM-C162 inhibited alpha-toxin (hla)-induced toxicity. Molecular docking and interaction analyses suggest that UM-C162 may bind directly to alpha-toxin. Its inhibitory activity was validated using a rabbit red blood cell haemolysis assay, yielding an IC50 of 36.97 µM. Co-incubation with recombinant alpha-toxin significantly reduced toxin-mediated injury to human alveolar epithelial (A549) cells, as observed by confocal microscopy, without causing cytotoxicity or cytolysis, as confirmed by MTS and lactate dehydrogenase assays. This protective effect did not result from inhibition of alpha-toxin oligomerisation, as UM-C162 failed to prevent deoxycholate-induced heptamer formation. Furthermore, real-time quantitative polymerase chain reaction analysis revealed that UM-C162 downregulates hla gene expression at the mRNA level. Collectively, these findings demonstrate that UM-C162 impairs S. aureus alpha-toxin activity and support its further development as a promising anti-virulence agent.
Insights
The small molecule UM-C162 effectively inhibits Staphylococcus aureus alpha-toxin, a key virulence factor. This compound shows promise as a novel anti-virulence agent against resistant bacterial infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Staphylococcus aureus is a major cause of healthcare-associated and community infections.
- Rising resistance to methicillin-resistant S. aureus and vancomycin-resistant S. aureus necessitates new anti-virulence strategies.
- UM-C162, a novel small molecule, has demonstrated potential in reducing S. aureus virulence and biofilm formation.
Purpose of the Study:
- To investigate the mechanism by which UM-C162 inhibits Staphylococcus aureus virulence.
- To specifically assess the effect of UM-C162 on alpha-toxin (hla) activity and expression.
- To evaluate UM-C162 as a potential anti-virulence therapeutic agent.
Main Methods:
- Molecular docking and interaction analyses to predict UM-C162 binding to alpha-toxin.
- Rabbit red blood cell haemolysis assay to determine inhibitory concentration (IC50).
- Confocal microscopy and cell viability assays (MTS, lactate dehydrogenase) to assess toxin-mediated cell injury and cytotoxicity.
- Real-time quantitative polymerase chain reaction (RT-qPCR) to analyze hla gene expression.
Main Results:
- UM-C162 demonstrated significant inhibition of alpha-toxin-induced toxicity with an IC50 of 36.97 µM.
- UM-C162 protected human alveolar epithelial (A549) cells from alpha-toxin-mediated injury without causing cytotoxicity.
- The compound downregulates hla gene expression at the mRNA level, suggesting transcriptional inhibition.
- UM-C162 did not inhibit alpha-toxin oligomerization, indicating a mechanism other than preventing heptamer formation.
Conclusions:
- UM-C162 effectively inhibits Staphylococcus aureus alpha-toxin activity.
- The compound acts by downregulating hla gene expression.
- UM-C162 represents a promising anti-virulence agent for treating S. aureus infections, particularly those involving resistant strains.
